Caedo Oncology

Caedo Oncology is an early-stage biotech focused on creating improved cancer treatments through unique immunotherapy approaches that trigger novel, caspase-independent programmed cell death pathways. Founded in 2020 based on research from Oslo University Hospital, the company's proprietary antibodies target cell surface proteins like CD47, CD99, and HLA class I molecules. Its main shareholder is the venture capital fund Sarsia Seed, and it has secured a significant grant from the Norwegian Research Council. The company is led by a team with deep experience in immunology, antibody engineering, and biotech commercialization.

Platform for discovering monoclonal antibodies that bind to cell surface proteins (CD47, CD99, HLA class I) and trigger novel, fast-acting, caspase-independent programmed cell death pathways in cancer cells.

Competes in the crowded CD47-targeting space against companies like Gilead (Forty Seven), ALX Oncology, and Pfizer (Trillium). Key differentiation is the direct induction of rapid, caspase-independent programmed cell death, a mechanism not common among other CD47 blockers that primarily function as phagocytosis checkpoint inhibitors.